Introduction
Isoleucine 50 located in the flap region of the HIV protease (PR) plays a key role in enzymatic function and protease inhibitor (PI) binding [1] , and changes in that position to leucine or valine determine the specific resistance to atazanavir (ATV) and amprenavir (APV), respectively.
ATV has a particular genotypic and phenotypic resistance profile compared with other PIs. The I50L substitution, found in clinical isolates from PI-naive patients failing an ATV-containing regimen [2] has been associated with increased susceptibility and no crossresistance to the other approved PIs [2] [3] [4] .
APV, a potent HIV type-1 (HIV-1) PI [5] , selects the key signature amino acid substitution I50V [6] [7] [8] , conferring minimal cross-resistance or even increasing the susceptibility to other PIs [6] [7] [8] [9] . APV and darunavir (DRV) share some specific resistance mutations [10] and the I50V mutation has shown an effect on DRV susceptibility [11] .
To evaluate the interplay between ATV and APV resistance at position 50 on the HIV PR, we investigated the genotypic and phenotypic effects of these two PIs in sequential or in combination cultures.
Methods

I50L-and I50V-containing viruses
In vitro selection HIV-LAI wild-type strain (HIV-LAI; AIDS Research and Reference Reagent Program, National Institutes of Health) [12] was serially passaged with ATV (BristolMyers Squibb) or APV (GlaxoSmithKline) alone, as previously reported [13] . Two patients displaying treatment failure while they  were on a PI-containing regimen with either I50V  (I15V/M46I/I50V/R57K/Q58E/L63P/V77I/V82I) or I50L change (K20R/E35D/M36I/M46MI/I50L/R57K/ L63LP/H69K/A71AV/G73GS) were selected. Gag-Pol PCR products amplified from these four position-50-mutated viruses were cloned into a genomic proviral vector (pJM11∆GPR) [14] .
In vivo selection
In vitro sequential and combined selection MT-4 cells were infected with I50V or I50L recombinant viruses in the presence of increasing concentrations of ATV or APV, respectively. In addition, HIV-LAI was serially passaged in MT-4 cells in the presence of increasing concentrations of ATV plus APV. As a control, Gag-Pol sequence from HIV-LAI was cloned and passaged without drug. Culture supernatants from each passage were collected and genotypic and phenotypic analyses were performed.
Genotypic analyses
Viral RNA was extracted (QIAamp viral RNA kit, Quiagen, Madrid, Spain), and the PR and cleavage site (CS) were amplified and sequenced using the Big-Dye ® Terminator v3.1 Cycle Sequencing kit and the ABI 3100 sequence analyser (Applied Biosystems, Madrid, Spain). Sequence analysis was performed using the Sequencher v.4.2 (Gene Codes Corporation, Ann Arbor, MI, USA) and GeneDoc version 2.6.001 software.
Phenotypic analyses
MT4-cells were infected with different viruses in the presence of serial dilutions of ATV, APV or DRV (Tibotec Pharmaceuticals) in triplicate. After 5 days of incubation at 37°C, the number of viable cells was monitored by the MTT method as previously described [15] . The sensitivity of all viruses to zidovudine (AZT; Sigma-Aldrich, Madrid, Spain) was performed as a control in each assay.
Results
In vitro and in vivo selected HIV-1 variants with changes at position 50 in PR
In an initial step, we generated in vitro HIV-LAI ATVresistant (V32VI/K43KT/M46ML/G48GR/I50L/ L63LP/A71V/I84IV/N88S/GagA431V) and APVresistant (L10F/V32I/L33LF/M46I/I47V/I50V/V82VI/ GagL449F) viruses (Supplementary Table 1 , Additional file 1). Gag-Pol fragments from these in vitro and the in vivo position-50-mutated PRs were cloned into pJM11∆GPR [14] and the following recombinant viruses were obtained: L10F/V32I/L33F/M46I/I47V/ I50V/ GagA431V/R444G/L449F (HIV-LAI-derived-I50V), M46L/I50L/L63P/A71V/N88S/GagE428D/ A431V (HIV-LAI-derived-I50L), M46I/I50V/Q58E/ L63P/V77I/V82I/GagI437L/L449V/R452S/P453L (patient-derived-I50V) and (K20R/M36I/I50L/L63P/ H69K/A71V/G73S/GagA431V (patient-derived-I50L; Tables 1 and 2 , week 0).
Sequential selection of recombinant viruses containing I50V PRs in the presence of ATV HIV-LAI-derived-I50V virus showed a fast reversion to wild type at position 50 (50I) when cultured in the presence of ATV (Table 1 ). After 17 weeks in culture, a 50I/L mixture variant emerged, and finally an I10F/V32I/L33F/ M46I/I50L/Q58EK/L63P/A71V/V77VI/I84V/N88NS mutant was selected. The CS region showed no changes in comparison with the initial virus ( Table 1) .
ATV also selected a change at position 50 in the patient-derived-I50V recombinant variant; however, in this case, the reversion to wild type (50I) was not observed and a V/L change was readily detected. The additional mutations V32I, A71V and I84I/V in the PR region and the accumulation of A431V substitution in the CS region were also detected in the last passage.
Phenotypically, highly resistant variants to ATV (>150-fold) and cross-resistant to APV and DRV were obtained at the last passage (Table 1) . During the process of acquisition of resistance to ATV, the change V to L at position 50 coincided with a high increase in the ATV resistance but also with a significant diminution in the APV and DRV resistance in both viruses (Table 1) .
Sequential selection of recombinant viruses containing I50L PRs in the presence of APV
Irrespective of the PR backgrounds used, the 10F, 33F and 84V mutations were selected in culture in both viruses (Table 2) . APV pressure did not modify the CS site of HIV-LAI-derived-I50L virus, but added a P453L substitution to the already existing A431V in the patient-derived-I50L virus.
Phenotypically, sequential APV pressure resulted in a significant increase in resistance to APV (99-and 69-fold for HIV-LAI-and patient-derived viruses, respectively) and DRV (3-and 6-fold change, respectively; Table 2 ). Conversely, the HIV-LAI-derived virus showed a reduction in resistance to ATV along the culture, whereas the patient-derived virus displayed a significant increase (Table 2) .
Combination culture of a HIV-LAI with ATV plus APV
Two independent experiments of ATV plus APV combined pressure, selected for almost identical viruses, containing the L10F, V32I, K45K/I, A71V and I84V mutations and only differing in an M46M/L substitution (Table 3) . It is important to note that changes at position 50 in the PR gene or in the CS were not observed in any of the experiments performed. The phenotypic analysis showed that the co-selection with ATV plus APV conferred reduced susceptibility to the three tested drugs (Table 3) .
Discussion
We designed an in vitro study to evaluate the evolution of wild type, I50L and I50V mutated PRs under the sequential or combined selective pressure of ATV and APV.
ATV pressure on recombinant viruses containing I50V PRs (HIV-LAI-and patient-derived) consistently selected the I50L substitution, suggesting that the acquisition of ATV resistance is restricted to the I50L pathway also in these mutated PRs. However, in PI-experienced patients who failed ATV therapy, the emergence of the I50L substitution occurs less frequently (10-30%) [16] [17] [18] than in PI-naive patients (100%) [2] . Consistent with this in vivo observation, the kinetics of phenotypic evolution observed in our sequential ATV pressure shows ATV resistance associated with early changes in different PR positions; however, at higher ATV concentrations, the I50L change emerges concomitant with a significant increase in ATV resistance. Although these finally selected viruses showed cross-resistance to the three tested drugs, it is worth noting that during the process of acquisition of resistance to ATV, the emergence of this 50L substitution, even in a highly mutated background, remarkably induced a significant decrease in resistance to APV and DRV. These results are in agreement with previous data [3, 4] , indicating that this change could counteract the reduced susceptibility caused by other resistance substitutions. However, the maintenance of the selective pressure could lead to the later acquisition of additional mutations that will continue to increase the resistance to these PIs.
APV pressure induced the appearance of L10F, L33F and I84V substitutions without changes at position 50 throughout the culture in both viruses. Although the emergence of resistance to APV is mainly associated with the substitution I50V, other alternative pathways have been described in vivo [8] . The presence of an I50L background in the PR might lead to constrained evolution of APV resistance, blocking the I50V pathway and forcing the evolution of resistance through these alternative pathways. Interestingly, a different evolution in the ATV susceptibility was observed between both viruses, as HIV-LAI-derived-I50L virus showed a clear reduction in resistance, whereas the patient-derived-I50L virus displayed a high increase along the culture. The different evolution could be explained by the distinct mutations already present in the background or by the selected change in the CS (P453L change in the patient-derived virus). To test the effect of this mutation on the phenotype, the mutation was reverted in the final APV-selected virus by site-directed mutagenesis. The P453 and L453 viruses had similar resistance profiles compared with the HIV-LAI virus: ATV-resistant (96-and 88-fold, respectively), APV (33-and 24-fold, respectively) and DRV-resistant (4-and 1.5-fold, respectively; FC et al., data not shown) indicating that the different evolution probably is not a result of the emergence of this mutation.
Finally, combined selection using ATV plus APV resulted in a resistant HIV-LAI variant without changes at position 50 in the PR or in the CS. Combination pressure might lead HIV PR to use alternative resistance pathways because the emerging I50V variants should be blocked by ATV; similarly, APV might block emerging I50L variants, according to the phenotypic data. In conclusion, different sequential or combined ATV-APV pressure selects cross-resistance with different mutational patterns. Cross-resistance can be achieved in the absence of changes at position 50 after combined pressure, or by selecting the I50L mutation after sequential APV-ATV pressure (irrespective of the order of addition of the drugs). Interestingly, selection of I50L variants during ATV pressure on PI-resistant viruses resulted in a high level of ATV-resistance, but a decrease in resistance to the other two PIs, suggesting that sequential treatment with ATV could have significant advantages in terms of the emergence of drug resistance.
